Alkahest, Inc.

25 articles with Alkahest, Inc.

• 

  Alzheimer’s Disease Insight Report: Current Therapies, Drug Pipeline and Outlook

  9/23/2019

  50 million people worldwide live with symptomatic Alzheimer's, which has no cure. In honor of September 21st being World Alzheimer's Day, we evaluated the current therapies, drugs in the pipeline and disease outlook.
• 

  Clinical Catch-up for August 19-23

  8/26/2019

  Biopharma companies large and small are involved in numerous clinical trials. Here’s a look at some of the top stories from last week.
• 

  Clinical Catch-up for July 29 – August 2

  8/5/2019

  Every week brings news of clinical trials, ranging from launches, first-patient dosing, full enrollment, interim data or final data. Here’s a look at some of the clinical trial news from last week.
• 

  BioSpace Movers and Shakers, July 26

  7/26/2019

  Biotech and pharma companies bolster their executive leadership and boards of directors with this week's appointments.

• Alkahest Presents Positive Results from Phase 2a Open Label Study of AKST4290 in Treatment-Naïve neovascular AMD at Retina World Congress

  3/25/2019

  Alkahest, Inc., a clinical stage biotechnology company focused on developing transformative therapies to treat age-related diseases, shared results yesterday from its open label study, ALK4290-201.

• Alkahest Doses First Subject in Phase 2 Clinical Trial of Lead Candidate in Patients with Severe Alzheimer's Disease

  3/18/2019

  Alkahest, Inc. announced the dosing of the first subject with severe Alzheimer's disease in a Phase 2 clinical trial of GRF6019 in collaboration with development partner Grifols.

• Alkahest to Present Results from Phase 2a Open Label Study of AKST4290 in wet AMD at Retina World Congress

  3/14/2019

  Alkahest, Inc. will present the results from its open label study evaluating AKST4290 for the treatment of wet age-related macular degeneration in treatment-naïve patients at the Retina World Congress in Fort Lauderdale, Florida on March 24, 2019 at 11:33 a.m. EST.

• Alkahest Announces Positive Top-Line Data from Two Phase 2a Studies of AKST4290 in Individuals with Wet Age-Related Macular Degeneration

  12/17/2018

  Both treatment naïve and treatment refractory individuals experienced improved visual acuity

• Alkahest Doses First Subject in Phase 2 Clinical Trial of GRF6021 in Patients with Parkinson's Disease and Cognitive Impairment

  12/4/2018

  Grant funding by The Michael J. Fox Foundation will support Phase 2 trial

• 

  BioSpace Movers and Shakers: Nov. 26

  11/26/2018

  In a short week leading up to Thanksgiving, several companies made leadership changes as they eye the coming year. We round up who made power moves this past week.
• 

  BioSpace Movers and Shakers Nov. 12

  11/12/2018

  Biopharma companies name new members of their leadership teams. Who made big moves this week?

• Alkahest Appoints Elizabeth Jeffords as Chief Commercial and Strategy Officer

  11/7/2018

  Alkahest, Inc. today announced the appointment of Elizabeth Jeffords as chief commercial and strategy officer. 

• Alkahest to Present at the Society for Neuroscience 48th Annual Meeting

  11/5/2018

  Presentations highlight a novel multifactorial approach to treating neurodegenerative diseases

• Alkahest Scientific Founder Tony Wyss-Coray Recognized as One of TIME Magazine's 50 Most Influential People in Health Care

  11/2/2018

  Alkahest Inc. announced today that Tony Wyss-Coray Ph.D., Alkahest's co-founder and board member was named to TIME Health's list of individuals who were most influential in transforming healthcare in 2018.  

• Alkahest Presentation at Clinical Trials in Alzheimer's Disease (CTAD) Conference October 26, 2018, Barcelona, Spain

  10/29/2018

  Alkahest provided update on their novel multifactorial approach to the treatment of Alzheimer's Disease

• 

  19 (at Least!) of TIME Magazine’s 50 Most Influential Healthcare People Have Biopharma Ties

  10/19/2018

  TIME Magazine came out with a list of the 50 most influential people in healthcare, dubbed The Health Care 50. A look through the list shows just how many ties and connections—as well as influence—this group has on the biopharma industry.

• Alkahest, Inc. Announces Key Appointment of Bruce Morimoto, PhD

  8/1/2018

  Bruce Morimoto joins Alkahest as Vice President, Drug Development Operations

• Alkahest to Present at Alzheimer's Association International Conference (AAIC) Annual Meeting July 22-26, 2018 Chicago, IL

  7/23/2018

  Presentations highlight a novel multifactorial approach to the treatment of Alzheimer's Disease

• Alkahest, Inc. Announces Key Appointment

  6/18/2018

  Michael Byrnes joins Alkahest as Chief Financial Officer

• Alkahest Receives Grant from Michael J. Fox Foundation; Funding Will Support Preclinical Evaluation of ALK4290 for Parkinson's Disease

  5/21/2018

  Alkahest, Inc. ("Alkahest"), a clinical-stage biotechnology company focused on developing innovative therapies to treat age-related diseases, today announced that it has been awarded a grant from The Michael J. Fox Foundation for Parkinson's Research (MJFF) entitled "Development of ALK4290 as a novel PD therapeutic" under the Principal Investigator S. Sakura Minami, Ph.D.